Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given an average rating of “Buy” by the four research firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.25.
Several analysts have recently commented on AMRX shares. Truist Financial reaffirmed a “buy” rating and issued a $9.00 price objective (up from $7.00) on shares of Amneal Pharmaceuticals in a report on Monday, May 6th. The Goldman Sachs Group upped their price objective on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a “buy” rating in a report on Monday, May 6th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Finally, Piper Sandler upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Thursday, March 21st.
Check Out Our Latest Analysis on AMRX
Hedge Funds Weigh In On Amneal Pharmaceuticals
Amneal Pharmaceuticals Stock Up 0.4 %
NASDAQ:AMRX opened at $6.75 on Friday. The company has a market cap of $2.08 billion, a PE ratio of -12.05 and a beta of 1.19. Amneal Pharmaceuticals has a twelve month low of $2.29 and a twelve month high of $7.25. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31. The company’s 50 day moving average is $6.42 and its two-hundred day moving average is $5.88.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its earnings results on Friday, May 3rd. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $659.19 million for the quarter, compared to the consensus estimate of $623.08 million. Amneal Pharmaceuticals had a negative net margin of 6.76% and a positive return on equity of 234.06%. Analysts anticipate that Amneal Pharmaceuticals will post 0.51 EPS for the current year.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Featured Articles
- Five stocks we like better than Amneal Pharmaceuticals
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- 10 Best Airline Stocks to Buy
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- What is the Nikkei 225 index?
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.